Current understanding of osteoporosis associated with liver disease

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 11, 2009, Pages 660-670

  Nakchbandi, Inaam A ^a   van der Merwe, Schalk W ^b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CALCITRIOL; CALCIUM; COLONY STIMULATING FACTOR 1; COPPER; CORTICOSTEROID; INTERLEUKIN 1; IRON; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; SOMATOMEDIN C; STRONTIUM RANELATE; VITAMIN D;

AGE; ALCOHOL CONSUMPTION; BILIARY CIRRHOSIS; BODY MASS; BONE DENSITY; BONE MASS; BONE REMODELING; CHOLESTATIC HEPATITIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HEREDITY; HUMAN; HYPOGONADISM; IMMUNE SYSTEM; LIVER DISEASE; LIVER DYSFUNCTION; LIVER INJURY; MALNUTRITION; MENOPAUSAL SYNDROME; MUSCLE ATROPHY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

HUMANS; LIVER DISEASES; OSTEOPOROSIS;

EID: 71049123195     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.166     Document Type: Review

References (104)

1. Collier, J. Bone disorders in chronic liver disease. Hepatology 46, 1271-1278 (2007).
2. Diamond, T. et al. Osteoporosis and skeletal fractures in chronic liver disease. Gut 31, 82-87 (1990).
3. Pares, A. & Guanabens, N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin. Liver Dis. 12, 407-424 (2008).
4. Caetano-Lopes, J., Canhao, H. & Fonseca, J. E. Osteoimmunology - the hidden immune regulation of bone. Autoimmun. Rev. 8, 250-255 (2009).
5. Takayanagi, H. Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304 (2007).
6. WHO. Prevention and management of osteoporosis. Report of a WHO scientific group (WHO, Geneva, 2003).
7. Hay, J. E. & Guichelaar, M. M. evaluation and management of osteoporosis in liver disease. Clin. Liver Dis. 9, 747-766 (2005).
8. Leslie, W. D., Bernstein, C. N., Leboff, M. S. & American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125, 941-966 (2003).
9. Bagur, A., Mautalen, C., Findor, J., Sorda, J. & Somoza, J. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif. Tissue Int. 63 385-390 (1998).
10. Benetti, A. et al. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: A controlled longitudinal study. J. Clin. Gastroenterol. 42, 306-311 (2008).
11. Guanabens, N. et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J. Hepatol. 42 573-577 (2005).
12. Guichelaar, M. M., Kendall, R., Malinchoc, M. & Hay, J. E. Bone mineral density before and after OLT: Long-term follow-up and predictive factors. Liver Transpl. 12, 1390-1402 (2006).
13. Pares, A. et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 33, 554-560 (2001).
14. Menon, K. V., Angulo, P., Weston, S., Dickson, E. R. & Lindor, K. D. Bone disease in primary biliary cirrhosis: Independent indicators and rate of progression. J. Hepatol. 35, 316-323 (2001).
15. Guichelaar, M. M., Malinchoc, M., Sibonga, J., Clarke, B. L. & Hay, J. E. Bone metabolism in advanced cholestatic liver disease: Analysis by bone histomorphometry. Hepatology 36, 895-903 (2002).
16. Guanabens, N. et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am. J. Gastroenterol. 85, 1356-1362 (1990).
17. Corazza, G. R. et al. early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig. Dis. Sci. 45, 1392-1399 (2000).
18. Gallego-Rojo, F. J. et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 28, 695-699 (1998).
19. Tsuneoka, K., Tameda, Y., Takase, K. & Nakano, T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J. Gastroenterol. 31, 669-678 (1996).
20. Masaki, K. et al. Longitudinal changes of bone mineral content with age in patients with cirrhosis of the liver. J. Gastroenterol. 33, 236-240 (1998).
21. Schiefke, I. et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J. Gastroenterol. 11, 1843-1847 (2005).
22. Arase, Y. et al. Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. J. Med. Virol. 80, 1302-1307 (2008).
23. Carey, E. J., Balan, v., Kremers, W. K. & Hay, J. E. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem. Liver Transpl. 9, 1166-1173 (2003).
24. Garcia-Valdecasas-Campelo, E. et al. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol. 41, 261-266 (2006).
25. Olsson, R., Johansson, C., Lindstedt, G. & Mellstrom, D. Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand. J. Gastroenterol. 29, 753-756 (1994).
26. Diamond, T., Stiel, D. & Posen, S. Osteoporosis in hemochromatosis: Iron excess, gonadal deficiency, or other factors? Ann. Intern. Med. 110, 430-436 (1989).
27. Diamond, T. H. et al. Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 96, 213-221 (1989).
28. Foresta, C., Schipilliti, M., Ciarleglio, F. A., Lenzi, A. & D'Amico, D. Male hypogonadism in cirrhosis and after liver transplantation. J. Endocrinol. Invest. 31, 470-478 (2008).
29. Bouillon, R. et al. Serum vitamin D metabolites and their binding protein in patients with liver cirrhosis. J. Clin. Endocrinol. Metab. 59, 86-89 (1984).
30. Skinner, R. K., Sherlock, S., Long, R. G. & Wilis, M. R. 25-Hydroxylation of vitamin D in primary biliary cirrhosis. Lancet 1, 720-721 (1977).
31. Herlong, H. F., Recker, R. R. & Maddrey, W. C. Bone disease in primary biliary cirrhosis: Histologic features and response to 25-hydroxyvitamin D. Gastroenterology 83, 103-108 (1982).
32. Matloff, D. S. et al. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 83 97-102 (1982).
33. Shiomi, S. et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. J. Gastroenterol. 34, 241-245 (1999).
34. Shiomi, S. et al. Calcitriol for bone disease in patients with cirrhosis of the liver. J. Gastroenterol. Hepatol. 14, 547-552 (1999).
35. Sambrook, P. & Cooper, C. Osteoporosis. Lancet 36, 2010-2018 (2006).
36. Scharf, J. G. et al. Insulin-like growth factor-I serum concentrations and patterns of insulinlike growth factor binding proteins in patients with chronic liver disease. J. Hepatol. 25 689-699 (1996).
37. Asomaning, K., Bertone-Johnson, E. R., Nasca, P. C., Hooven, F. & Pekow, P. S. The association between body mass index and osteoporosis in patients referred for a bone mineral density examination. J. Womens Health (Larchmt) 15, 1028-1034 (2006).
38. Friedman, J. M. & Halaas, J. L. Leptin and the regulation of body weight in mammals. Nature 39, 763-770 (1998).
39. Otte, C. et al. expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp. Clin. Endocrinol. Diabetes 112, 10-17 (2004).
40. Piche, T. et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J. Viral Hepat. 11 91-96 (2004).
41. Ormarsdottir, S. et al. Inverse relationship between circulating levels of leptin and bone mineral density in chronic liver disease. J. Gastroenterol. Hepatol. 16, 1409-1414 (2001).
42. Szalay, F. et al. Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 17, 923-928 (2005).
43. Guggenbuhl, P. et al. Bone mineral density in men with genetic hemochromatosis and HFe gene mutation. Osteoporos. Int. 16, 1809-1814 (2005).
44. Le Gars, L., Grandpierre, C., Chazouilleres, O., Berenbaum, F. & Poupon, R. Bone loss in primary biliary cirrhosis: Absence of association with severity of liver disease. Joint Bone Spine 69, 195-200 (2002).
45. Pares, A., Guanabens, N. & Rodes, J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 17, 311-315 (2005).
46. Lakatos, L. P. et al. vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 14, 733-740 (2002).
47. Springer, J. E. et al. vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 118, 145-151 (2000).
48. Rubin, L. A. et al. Determinants of peak bone mass: Clinical and genetic analyses in a young female Canadian cohort. J. Bone Miner. Res. 14, 633-643 (1999).
49. vogel, A., Strassburg, C. P. & Manns, M. P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 35, 126-131 (2002).
50. Lakatos, P. L. et al. Insulin-like growth factor I gene microsatellite repeat, collagen type Ialpha1 gene Sp1 polymorphism, and bone disease in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 16, 753-759 (2004).
51. Sinigaglia, L. et al. Bone and joint involvement in genetic hemochromatosis: Role of cirrhosis and iron overload. J. Rheumatol. 24, 1809-1813 (1997).
52. valenti, L. et al. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos. Int. 20, 549-555 (2009).
53. Schnitzler, C. M., Schnaid, E., MacPhail, A. P., Mesquita, J. M. & Robson, H. J. Ascorbic acid deficiency, iron overload and alcohol abuse underlie the severe osteoporosis in black African patients with hip fractures - a bone histomorphometric study. Calcif. Tissue Int. 76, 79-89 (2005).
54. voskaridou, E. & Terpos, E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br. J. Haematol. 127, 127-139 (2004).
55. Diamond, T., Pojer, R., Stiel, D., Alfrey, A. & Posen, S. Does iron affect osteoblast function? Studies in vitro and in patients with chronic liver disease. Calcif. Tissue Int. 48, 373-379 (1991).
56. Hegedus, D. et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J. Bone Miner. Res. 17, 1961-1967 (2002).
57. Janes, C. H. et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J. Clin. Invest. 95, 2581-2586 (1995).
58. Smith, D. L. et al. Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. J. Clin. Densitom. 9, 105-113 (2006).
59. Batta, A. K. et al. effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 10, 414-419 (1989).
60. Lindor, K. D., Janes, C. H., Crippin, J. S., Jorgensen, R. A. & Dickson, E. R. Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference? Hepatology 21, 389-392 (1995).
61. Ringe, J. D. & Farahmand, P. Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates. Clin. Rheumatol. 26, 474-484 (2007).
62. Czaja, A. J. Safety issues in the management of autoimmune hepatitis. Expert Opin. Drug Saf. 7, 319-333 (2008).
63. van der Merwe, S. W. et al. effect of rapamycin on hepatic osteodystrophy in rats with portasystemic shunting. World J. Gastroenterol. 12, 4504-4510 (2006).
64. van der Merwe, S. W. et al. Hepatic osteodystrophy in rats results mainly from portasystemic shunting. Gut 52, 580-585 (2003).
65. Yakar, S. et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl Acad. Sci. USA 96, 7324-7329 (1999).
66. Yakar, S. et al. Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110, 771-781 (2002).
67. Cemborain, A. et al. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J. Hepatol. 28, 122-131 (1998).
68. Gillberg, P., Mallmin, H., Petren-Mallmin, M., Ljunghall, S. & Nilsson, A. G. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J. Clin. Endocrinol. Metab. 87, 4900-4906 (2002).
69. Ormarsdottir, S. et al. Circulating levels of insulin-like growth factors and their binding proteins in patients with chronic liver disease: Lack of correlation with bone mineral density. Liver 21, 123-128 (2001).
70. Heaney, R. P., Recker, R. R. & Saville, P. D. Menopausal changes in bone remodeling. J. Lab. Clin. Med. 92, 964-970 (1978).
71. Insogna, K. et al. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. J. Bone Miner. Res. 17 (Suppl. 2), N108-N116 (2002).
72. Syed, F. & Khosla, S. Mechanisms of sex steroid effects on bone. Biochem. Biophys. Res. Commun. 328, 688-696 (2005).
73. Okazaki, R. et al. estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (eR) alpha or beta. Endocrinology 143, 2349-2356 (2002).
74. Hodgson, S. F. et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann. Intern. Med. 103, 855-860 (1985).
75. Mitchison, H. C., Malcolm, A. J., Bassendine, M. F. & James, O. F. Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 94, 463-470 (1988).
76. Stellon, A. J., Webb, A., Compston, J. & Williams, R. Low bone turnover state in primary biliary cirrhosis. Hepatology 7, 137-142 (1987).
77. Dresner-Pollak, R. et al. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats. Gastroenterology 134, 259-267 (2008).
78. Diamond, T., Stiel, D., Lunzer, M., Wilkinson, M. & Posen, S. ethanol reduces bone formation and may cause osteoporosis. Am. J. Med. 86, 282-288 (1989).
79. Guanabens, N. et al. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J. Bone Miner. Res. 13, 731-738 (1998).
80. Gonzalez-Calvin, J. L. et al. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J. Clin. Endocrinol. Metab. 89, 4325-4330 (2004).
81. Herman, S., Kronke, G. & Schett, G. Molecular mechanisms of inflammatory bone damage: Emerging targets for therapy. Trends Mol. Med. 14 245-253 (2008).
82. Clay, P. G., voss, L. E., Williams, C. & Daume, E. C. valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann. Pharmacother. 42, 670-679 (2008).
83. Kotake, S. et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 44, 1003-1012 (2001).
84. Tilg, H., Moschen, A. R., Kaser, A., Pines, A. & Dotan, I. Gut, inflammation and osteoporosis: Basic and clinical concepts. Gut 57, 684-694 (2008).
85. Horwood, N. J. et al. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265, 144-150 (1999).
86. Kim, Y. G. et al. Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 357, 1046-1052 (2007).
87. Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682 (2006).
88. Lemmers, A. et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49, 646-657 (2009).
89. Simonet, W. S. et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
90. Szalay, F. et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J. Hepatol. 38, 395-400 (2003).
91. Fabrega, E. et al. Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int. 25, 305-310 (2005).
92. Moschen, A. R. et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J. Hepatol. 43 973-983 (2005).
93. Monegal, A. et al. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. Liver Int. 27, 492-497 (2007).
94. Olivier, B. J. et al. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia. Hepatology 47, 259-267 (2008).
95. Pfeilschifter, J., Chenu, C., Bird, A., Mundy, G. R. & Roodman, G. D. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J. Bone Miner. Res. 4, 113-118 (1989).
96. Diez Ruiz, A. et al. Tumour necrosis factor, interleukin-1 and interleukin-6 in alcoholic cirrhosis. Alcohol Alcohol. 28, 319-323 (1993).
97. Hanck, C., Rossol, S., Bocker, U., Tokus, M. & Singer, M. v. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol. 33, 606-608 (1998).
98. Decker, T., Lohmann-Matthes, M. L., Karck, U., Peters, T. & Decker, K. Comparative study of cytotoxicity, tumor necrosis factor, and prostaglandin release after stimulation of rat Kupffer cells, murine Kupffer cells, and murine inflammatory liver macrophages. J. Leukoc. Biol. 45, 139-146 (1989).
99. Moursi, A. M. et al. Fibronectin regulates calvarial osteoblast differentiation. J. Cell. Sci. 109, 1369-1380 (1996).
100. Sakai, T. et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat. Med. 7, 324-330 (2001).
101. Kawelke, N. et al. Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J. Bone Miner. Res. 23, 1278-1286 (2008).
102. Xu, G. et al. Gene expression and synthesis of fibronectin isoforms in rat hepatic stellate cells. Comparison with liver parenchymal cells and skin fibroblasts. J. Pathol. 183, 90-98 (1997).
103. Marie, P. J. Strontium ranelate: A physiological approach for optimizing bone formation and resorption. Bone 38 (2 Suppl. 1), S10-S14 (2006).
104. Oste, L. et al. Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats. Kidney Int. 67, 920-930 (2005).